This platform is basically expandable to generate CAR-T cells co-expressing a CSPG4-CAR together with a CAR specific for one of the antigens mentioned above to simultaneously eradicate CSPG4-negative ovarian cancer cells. This evidence concerns the gene CSPG4 and ovarian carcinoma.